{"ticker": {"uuid": "6e3042d1-238b-40a1-83af-b061f6f9ed58", "symbol": "ESLA", "name": "Estrella Immunopharma Inc.", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Enterprise value to EBIT forward of Estrella Immunopharma, Inc. \u2013 NASDAQ:ESLAW", "summary": "This article provides financial information for Estrella Immunopharma, Inc. (NASDAQ:ESLAW), focusing on its enterprise value to EBIT forward metric on TradingView. It highlights that the market was closed and no trades occurred, presenting an overview of the company's financial d", "url": "https://www.tradingview.com/symbols/NASDAQ-ESLAW/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-07-19T14:40:10", "published_display": "19 Jul 2026 14:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Enterprise value to revenue forward of Estrella Immunopharma, Inc. \u2013 NASDAQ:ESLAW", "summary": "The article focuses on the enterprise value to revenue forward metric for Estrella Immunopharma, Inc., traded on NASDAQ under the symbol ESLAW. It appears to be a financial data page from TradingView, providing an overview of the company's financial metrics. The core content is t", "url": "https://www.tradingview.com/symbols/NASDAQ-ESLAW/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-16T12:13:47", "published_display": "16 Jul 2026 12:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Estrella Immunopharma, Inc. \u2013 NASDAQ:ESLAW", "summary": "The article provides information about the \"Price to earnings forward\" for Estrella Immunopharma, Inc. (NASDAQ: ESLAW). It notes that the market was closed with no trades. The period, value, and change for this metric are mentioned as being made by humans.", "url": "https://www.tradingview.com/symbols/NASDAQ-ESLAW/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-16T04:03:53", "published_display": "16 Jul 2026 04:03", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Enterprise value to revenue forward of Estrella Immunopharma, Inc. \u2013 NASDAQ:ESLA", "summary": "This article provides financial information for Estrella Immunopharma, Inc. (NASDAQ: ESLA), focusing on its enterprise value to revenue forward. It appears to be a stub or a data-focused page from TradingView, offering an overview of the company's financials within the biotechnol", "url": "https://www.tradingview.com/symbols/NASDAQ-ESLA/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-09T17:11:25", "published_display": "09 Jul 2026 17:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ESLA: Abbott Cooper PLLC Announces Investigation on Behalf of Estrella Immunopharma, Inc. Stockholders", "summary": "Abbott Cooper PLLC has initiated an investigation into Estrella Immunopharma, Inc. (ESLA) to determine if its board of directors breached fiduciary duties or committed other wrongdoing. The firm is inviting stockholders to contact them to learn more about their legal rights, oper", "url": "https://www.globenewswire.com/news-release/2026/07/09/3324530/0/en/esla-abbott-cooper-pllc-announces-investigation-on-behalf-of-estrella-immunopharma-inc-stockholders.html", "source_name": "GlobeNewswire", "published_at": "2026-07-09T14:11:26", "published_display": "09 Jul 2026 14:11", "sentiment": "negative", "sentiment_pct": 29, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Estrella Immunopharma, Inc. \u2013 NASDAQ:ESLA", "summary": "This article provides a brief financial overview for Estrella Immunopharma, Inc. (NASDAQ: ESLA), specifically focusing on its forward price-to-sales ratio. It presents the company's stock information, market status, and links to various financial data on TradingView, while emphas", "url": "https://www.tradingview.com/symbols/NASDAQ-ESLA/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-09T11:40:18", "published_display": "09 Jul 2026 11:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Investigation launched into Estrella Immunopharma's board for possible fiduciary breaches", "summary": "Abbott Cooper PLLC has initiated an investigation into Estrella Immunopharma, Inc.'s board of directors to determine if they violated fiduciary duties or engaged in wrongdoing. The investigation, which could lead to legal action, aims to protect stockholder interests given that E", "url": "https://pluang.com/en/news-feed/esla-penyelidikan-hukum-untuk-pemegang-saham", "source_name": "Pluang", "published_at": "2026-07-09T02:40:18", "published_display": "09 Jul 2026 02:40", "sentiment": "negative", "sentiment_pct": 14, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Estrella Immunopharma, Inc. \u2013 BOATS:ESLAW", "summary": "This article provides financial information for Estrella Immunopharma, Inc. (ESLAW) on TradingView, specifically focusing on its forward price-to-earnings ratio. It indicates that no trades have occurred and presents an overview of the company's financial data on the platform. Th", "url": "https://www.tradingview.com/symbols/BOATS-ESLAW/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-01T00:10:13", "published_display": "01 Jul 2026 00:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Estrella Immunopharma, Inc. (ESLA) 8-K Filing: Shareholder Vote Results & Company Details \u2013 June 2026", "summary": "Estrella Immunopharma, Inc. announced the results of its Combined 2025/2026 Annual Meeting of Stockholders held on June 29, 2026. The meeting saw strong shareholder engagement with 70.5% of outstanding shares represented, confirming a quorum. While the specific proposal details w", "url": "https://www.minichart.com.sg/2026/06/30/estrella-immunopharma-inc-esla-8-k-filing-shareholder-vote-results-company-details-june-2026/", "source_name": "Minichart", "published_at": "2026-06-30T22:25:00", "published_display": "30 Jun 2026 22:25", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Estrella Immunopharma (ESLA) investors back 2026 auditor at virtual annual meeting", "summary": "Estrella Immunopharma, Inc. (ESLA) stockholders ratified the appointment of Macias Gini & O\u2019Connell LLP as their independent registered public accounting firm for the fiscal year ending December 31, 2026, during a virtual annual meeting on June 29, 2026. A substantial quorum was ", "url": "https://www.stocktitan.net/sec-filings/ESLA/8-k-estrella-immunopharma-inc-reports-material-event-63d41f7a04b3.html", "source_name": "Stock Titan", "published_at": "2026-06-30T21:10:00", "published_display": "30 Jun 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Estrella Immunopharma, Inc. \u2013 BOATS:ESLAW", "summary": "This article provides financial information for Estrella Immunopharma, Inc. (ESLAW), specifically focusing on its enterprise value to EBITDA forward metric. The content indicates that the market is closed, with no trades observed, and presents this data as part of TradingView's f", "url": "https://www.tradingview.com/symbols/BOATS-ESLAW/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-30T20:10:00", "published_display": "30 Jun 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Estrella Immunopharma, Inc. Actuals & Estimates (NASDAQ:ESLA)", "summary": "This article provides an overview of Estrella Immunopharma, Inc. (ESLA) stock performance, including current trading price, historical highs and lows, and analyst forecasts. It details financial actuals and estimates for the company, covering income statements, balance sheets, an", "url": "https://www.tradingview.com/symbols/NASDAQ-ESLA/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-25T20:09:18", "published_display": "25 Jun 2026 20:09", "sentiment": "negative", "sentiment_pct": 40, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Estrella Immunopharma Inc (ESLA) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for Estrella Immunopharma Inc (ESLA), detailing its previous and expected future EPS. While the company's financial health, valuation, price momentum, and institutional confidence usually involve comprehensive data, relevant information ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-esla/earnings", "source_name": "TradingKey", "published_at": "2026-06-21T19:42:17", "published_display": "21 Jun 2026 19:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Estrella Immunopharma Inc (ESLA) Risk Assessment: Volatility, Financial Risk & Investment Risk", "summary": "This article provides a risk assessment for Estrella Immunopharma Inc (ESLA), detailing various volatility and risk metrics. It includes data points such as Beta vs S&P 500 index, Maximum Drawdown, Realised Volatility, and Daily Upside/Downside Volatility over different periods. ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-esla/risk-assesment", "source_name": "TradingKey", "published_at": "2026-06-21T19:39:34", "published_display": "21 Jun 2026 19:39", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Estrella Immunopharma Inc (ESLA) Financial Health: Profitability & Balance Sheet Analysis", "summary": "This article provides a financial health analysis of Estrella Immunopharma Inc (ESLA) through the lens of TradingKey. It highlights that critical financial data necessary to assess profitability, balance sheet, operational efficiency, growth potential, and shareholder returns hav", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-esla/financial-health", "source_name": "TradingKey", "published_at": "2026-06-21T19:10:54", "published_display": "21 Jun 2026 19:10", "sentiment": "negative", "sentiment_pct": 28, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Estrella Immunopharma Inc (ESLA) Institutional Confidence", "summary": "This article from TradingKey provides an overview of Estrella Immunopharma Inc (ESLA)'s institutional confidence. It details the institutional shareholding and shareholder activity, listing major holders like Eureka Therapeutics Inc, Renaissance Technologies LLC, Geode Capital Ma", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-esla/sentiment", "source_name": "TradingKey", "published_at": "2026-06-21T18:10:54", "published_display": "21 Jun 2026 18:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Estrella Immunopharma Inc (ESLA) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Estrella Immunopharma Inc (ESLA), detailing its support, resistance, indicators, and moving averages. According to the analysis, various technical indicators and moving averages suggest a \"Sell\" signal for the stock, with 0 buy signal", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-esla/technical", "source_name": "TradingKey", "published_at": "2026-06-21T17:10:54", "published_display": "21 Jun 2026 17:10", "sentiment": "negative", "sentiment_pct": 19, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Estrella Immunopharma Inc (ESLA) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis for Estrella Immunopharma Inc (ESLA), noting that key financial ratios such as P/E, P/B, P/S, and P/CF are not yet disclosed by the company. It displays the current stock price, market capitalization, and indicates that the data is delay", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-esla/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-21T17:09:40", "published_display": "21 Jun 2026 17:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Estrella Immunopharma Inc (ESLAW) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution \u2014 TradingKey", "summary": "This article provides an overview of Estrella Immunopharma Inc (ESLAW), focusing on its revenue breakdown and company profile. It notes that relevant data regarding business segments, regional revenue, and profit contribution have not been disclosed by the company yet. The page a", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-eslaw/revenue", "source_name": "TradingKey", "published_at": "2026-06-18T11:41:06", "published_display": "18 Jun 2026 11:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Estrella Immunopharma Inc (ESLAW) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "This article details the shareholder structure of Estrella Immunopharma Inc (ESLAW), focusing on institutional holdings and major shareholders. It provides a quarterly breakdown of institutional share ownership and lists active institutional investors with their respective shares", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-eslaw/ownership", "source_name": "TradingKey", "published_at": "2026-06-18T11:41:06", "published_display": "18 Jun 2026 11:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Estrella Immunopharma Inc (ESLAW) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of Estrella Immunopharma Inc (ESLAW) focusing on its dividend and stock split history. It notes that the company has distributed $0.00 USD in dividends over the past five years and shows no data for past stock splits. The piece is primarily a dat", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-eslaw/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-18T11:41:06", "published_display": "18 Jun 2026 11:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Estrella Immunopharma Inc (ESLA) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of Estrella Immunopharma Inc's (ESLA) dividend history and stock split information. It notes that the company has not distributed any dividends over the past five years and has no recorded stock split events. The page also displays current stock ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-esla/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-18T02:40:28", "published_display": "18 Jun 2026 02:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Estrella Immunopharma Inc (ESLAW) Institutional Confidence", "summary": "This article provides details on the institutional confidence score for Estrella Immunopharma Inc (ESLAW), along with its stock performance data. It lists several institutional shareholders and their shareholdings or changes in holdings, highlighting notable movements such as red", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-eslaw/sentiment", "source_name": "TradingKey", "published_at": "2026-06-18T02:40:28", "published_display": "18 Jun 2026 02:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Estrella Immunopharma Inc (ESLAW) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for Estrella Immunopharma Inc (ESLAW), stating that relevant data for EPS, Revenue, and Net Profit forecasts have not yet been disclosed by the company. It notes the stock's current trading price and highlights the absence of key financi", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-eslaw/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T02:40:28", "published_display": "18 Jun 2026 02:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Estrella Immunopharma Inc. (ESLA) Stock Price | Live Quotes & Charts | NASDAQ", "summary": "This page provides live quotes and charts for Estrella Immunopharma Inc. (ESLA) stock. As of the data provided, ESLA is trading at $1.06, down $0.02 (-1.85%). The article notes that there are no analyst ratings or earning information currently available for the company.", "url": "https://stockstotrade.com/quote/ESLA", "source_name": "StocksToTrade", "published_at": "2026-06-13T16:09:56", "published_display": "13 Jun 2026 16:09", "sentiment": "negative", "sentiment_pct": 39, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Estrella Immunopharma (ESLA) sets virtual 2026 meeting to ratify auditor", "summary": "Estrella Immunopharma, Inc. (ESLA) will hold a virtual Combined 2025/2026 Annual Meeting of Stockholders on June 29, 2026, to ratify the appointment of Macias Gini & O\u2019Connell LLP as their independent registered public accounting firm for the fiscal year ending December 31, 2026.", "url": "https://www.stocktitan.net/sec-filings/ESLA/def-14a-estrella-immunopharma-inc-definitive-proxy-statement-11ec4954b9fb.html", "source_name": "Stock Titan", "published_at": "2026-05-27T21:39:37", "published_display": "27 May 2026 21:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Estrella CEO and CFO head to Plaza Hotel for investor meetings", "summary": "Estrella Immunopharma, a clinical-stage biopharmaceutical company, announced that its CEO and CFO will attend the D. Boral Capital 2026 Global Conference at The Plaza Hotel. They will be participating in one-on-one investor meetings to discuss the company's CD19 and CD22-targeted", "url": "https://www.stocktitan.net/news/ESLA/estrella-immunopharma-to-participate-in-the-d-boral-capital-global-19ufojqfo00a.html", "source_name": "Stock Titan", "published_at": "2026-05-24T08:10:17", "published_display": "24 May 2026 08:10", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Estrella Immunopharma, Inc. 1Q 2026: Net income $(2.29M), EPS $(0.05) \u2014 10-Q Summary", "summary": "Estrella Immunopharma, Inc. (ESLA) reported a net loss of $(2.29M) and a diluted loss per share of $(0.05) for the first quarter of 2026. This compares to a net loss of $(2.10M) and a diluted loss per share of $(0.06) in the same quarter last year. Key business highlights include", "url": "https://www.tradingview.com/news/tradingview:88655df7313e5:0-estrella-immunopharma-inc-1q-2026-net-income-2-29m-eps-0-05-10-q-summary/", "source_name": "TradingView", "published_at": "2026-05-18T10:39:18", "published_display": "18 May 2026 10:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[NT 10-Q] Estrella Immunopharma, Inc. SEC Filing", "summary": "Estrella Immunopharma, Inc. (ESLA) has filed a Form NT 10-Q, notifying the SEC of a late filing for its Quarterly Report on Form 10-Q for the period ended March 31, 2026. The company attributes the delay to administrative issues and expects to file the report within five calendar", "url": "https://www.stocktitan.net/sec-filings/ESLA/nt-10-q-estrella-immunopharma-inc-sec-filing-c5e46cfd1485.html", "source_name": "Stock Titan", "published_at": "2026-05-16T04:39:57", "published_display": "16 May 2026 04:39", "sentiment": "negative", "sentiment_pct": 39, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Estrella Immunopharma CFO Xu Jiandong buys $2,594 in stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxNanpmcXJ2dkx5SUxBcFN3bDVRUWtrVEZ5U3gyczJIM0MxblhPYzRzMnk4WFBSOFdqU2I2WHQ1OGVNVm83dkItVkU3d1kyTXI0R21zV2htXzZSeTdwbVE2RXNLTWlzcF9rVTFZM25ZWUM5NnV1LXpEUTJxelNwQ2dpS3F1VktOb1hlUVRteE4xdnlSaldNUUprdTdwRm1IZVp6RkxJY0VOLTFqQXNqWnMwWGRheUtCejZjREgyczRn?oc=5", "source_name": "Investing.com", "published_at": "2026-04-29T07:00:00+00:00", "published_display": "29 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Estrella Immunopharma, Inc. (NASDAQ: ESLA) Receives Initiating Coverage with a Valuation of $12.00/Share from Zacks Small-Cap Research", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwJBVV95cUxOb3ZQeUc1b2NtaWhWZGJ5WnNqSmJpVXh5TUZJZkhxMTBYcTZtMktwd1AtbXNEcnd1Yi1rM2ZsNldEekZ1MWoxcXNRYUtxbU1Ld0tzeWJ2OUdYdkVnUTdrZURrS2pUNy1PcGswbHlpVWUyNk1DZ08xVG5CSG9MNzlDa2lOVlMtRW54dnU4ZmVqMF9ZaDNQekJRRmVYQ28zU1hTaklOaUd1XzBxVjJpS1kyT18wMG93MmJUeG1JWEdacXUxRGV5cEdHWmJZeV9DYUp4a2RSaFRreGZBc0pJaW02eGZVMnlBTVh1WHVOdHNDeGdpd3laTGc5TWlOQ0psSlFvdWl3TkphVFBoSzR6ZkN0YzZTSlZrcGM?oc=5", "source_name": "Business Wire", "published_at": "2026-03-23T07:00:00+00:00", "published_display": "23 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Estrella Immunopharma Announces Closing of $8.0 Million Registered Direct Offering and Concurrent Private Placement", "summary": "", "url": "https://news.google.com/rss/articles/CBMi6gFBVV95cUxQeGR0d1d6MjdNT3FsZzFIQUZHSGNfLTAyN3BRUjNYbWNJYlhaenR5bS12ZmJhb2wtb3NQYlZBNk5fdERhbjhsSXRJTkpZZ0wtMDJ0a3lrY2JSbFhsUHBiLVhlb1ZuX0taaGs0cXFybE9uSmg3MGY1R1hKNlhJM3NmVmpLZFFka3dnWDRCVTI0NTBXZTA5a1JzdjhmZXRCTHdhRndobE82U3hfMEhPWTlXSDlBLTZCQ0M4WW1mVThCY01RRnRIWHJJU2lGUlAtUnhPcDBhOGh4RkNham1pTjYyVjZWUHJrTl81NkE?oc=5", "source_name": "BioSpace", "published_at": "2026-01-07T08:00:00+00:00", "published_display": "07 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Estrella Immunopharma (ESLA) FDA Approvals, PDUFA Dates & Drug Alerts 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMiaEFVX3lxTE1GOEY4RHRWWHBVLVZaWVg2NVlwS1JURllKRlBSQXNDNWFhdy1MeWFnM25XZmxIYk1MMHd1ZnNVeFM5RE1OV2JYeEllMnkwcFJpZ3phWHEwclhuTW83Uk8yRHhzb1FicXBL?oc=5", "source_name": "MarketBeat", "published_at": "2025-07-10T03:16:04+00:00", "published_display": "10 Jul 2025 03:16", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Estrella Immunopharma (ESLA) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE9tUFdKM2E1S01qeDVIN0w3S19TMEhmaXdlZUZuTTVTLU1iRkJvdk0ya3Q2VDBFZzRxY0gxT21zY3llckVHMFp3Y0tfZzJ1MWdDYXJF?oc=5", "source_name": "Stock Titan", "published_at": "2025-05-01T18:06:39+00:00", "published_display": "01 May 2025 18:06", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Enterprise value to EBIT forward of Estrella Immunopharma, Inc. \u2013 NASDAQ:ESLAW", "summary": "This article provides financial information for Estrella Immunopharma, Inc. (NASDAQ:ESLAW), focusing on its enterprise value to EBIT forward metric on TradingView. It highlights that the market was closed and no trades occurred, presenting an overview of the company's financial d", "url": "https://www.tradingview.com/symbols/NASDAQ-ESLAW/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-07-19T14:40:10", "published_display": "19 Jul 2026 14:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Estrella Immunopharma, Inc. \u2013 NASDAQ:ESLAW", "summary": "The article focuses on the enterprise value to revenue forward metric for Estrella Immunopharma, Inc., traded on NASDAQ under the symbol ESLAW. It appears to be a financial data page from TradingView, providing an overview of the company's financial metrics. The core content is t", "url": "https://www.tradingview.com/symbols/NASDAQ-ESLAW/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-16T12:13:47", "published_display": "16 Jul 2026 12:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Estrella Immunopharma, Inc. \u2013 NASDAQ:ESLAW", "summary": "The article provides information about the \"Price to earnings forward\" for Estrella Immunopharma, Inc. (NASDAQ: ESLAW). It notes that the market was closed with no trades. The period, value, and change for this metric are mentioned as being made by humans.", "url": "https://www.tradingview.com/symbols/NASDAQ-ESLAW/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-16T04:03:53", "published_display": "16 Jul 2026 04:03", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Estrella Immunopharma, Inc. \u2013 NASDAQ:ESLA", "summary": "This article provides financial information for Estrella Immunopharma, Inc. (NASDAQ: ESLA), focusing on its enterprise value to revenue forward. It appears to be a stub or a data-focused page from TradingView, offering an overview of the company's financials within the biotechnol", "url": "https://www.tradingview.com/symbols/NASDAQ-ESLA/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-09T17:11:25", "published_display": "09 Jul 2026 17:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ESLA: Abbott Cooper PLLC Announces Investigation on Behalf of Estrella Immunopharma, Inc. Stockholders", "summary": "Abbott Cooper PLLC has initiated an investigation into Estrella Immunopharma, Inc. (ESLA) to determine if its board of directors breached fiduciary duties or committed other wrongdoing. The firm is inviting stockholders to contact them to learn more about their legal rights, oper", "url": "https://www.globenewswire.com/news-release/2026/07/09/3324530/0/en/esla-abbott-cooper-pllc-announces-investigation-on-behalf-of-estrella-immunopharma-inc-stockholders.html", "source_name": "GlobeNewswire", "published_at": "2026-07-09T14:11:26", "published_display": "09 Jul 2026 14:11", "sentiment": "negative", "sentiment_pct": 29, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Estrella Immunopharma, Inc. \u2013 NASDAQ:ESLA", "summary": "This article provides a brief financial overview for Estrella Immunopharma, Inc. (NASDAQ: ESLA), specifically focusing on its forward price-to-sales ratio. It presents the company's stock information, market status, and links to various financial data on TradingView, while emphas", "url": "https://www.tradingview.com/symbols/NASDAQ-ESLA/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-09T11:40:18", "published_display": "09 Jul 2026 11:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Investigation launched into Estrella Immunopharma's board for possible fiduciary breaches", "summary": "Abbott Cooper PLLC has initiated an investigation into Estrella Immunopharma, Inc.'s board of directors to determine if they violated fiduciary duties or engaged in wrongdoing. The investigation, which could lead to legal action, aims to protect stockholder interests given that E", "url": "https://pluang.com/en/news-feed/esla-penyelidikan-hukum-untuk-pemegang-saham", "source_name": "Pluang", "published_at": "2026-07-09T02:40:18", "published_display": "09 Jul 2026 02:40", "sentiment": "negative", "sentiment_pct": 14, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Estrella Immunopharma, Inc. \u2013 BOATS:ESLAW", "summary": "This article provides financial information for Estrella Immunopharma, Inc. (ESLAW) on TradingView, specifically focusing on its forward price-to-earnings ratio. It indicates that no trades have occurred and presents an overview of the company's financial data on the platform. Th", "url": "https://www.tradingview.com/symbols/BOATS-ESLAW/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-01T00:10:13", "published_display": "01 Jul 2026 00:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Estrella Immunopharma, Inc. (ESLA) 8-K Filing: Shareholder Vote Results & Company Details \u2013 June 2026", "summary": "Estrella Immunopharma, Inc. announced the results of its Combined 2025/2026 Annual Meeting of Stockholders held on June 29, 2026. The meeting saw strong shareholder engagement with 70.5% of outstanding shares represented, confirming a quorum. While the specific proposal details w", "url": "https://www.minichart.com.sg/2026/06/30/estrella-immunopharma-inc-esla-8-k-filing-shareholder-vote-results-company-details-june-2026/", "source_name": "Minichart", "published_at": "2026-06-30T22:25:00", "published_display": "30 Jun 2026 22:25", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Estrella Immunopharma (ESLA) investors back 2026 auditor at virtual annual meeting", "summary": "Estrella Immunopharma, Inc. (ESLA) stockholders ratified the appointment of Macias Gini & O\u2019Connell LLP as their independent registered public accounting firm for the fiscal year ending December 31, 2026, during a virtual annual meeting on June 29, 2026. A substantial quorum was ", "url": "https://www.stocktitan.net/sec-filings/ESLA/8-k-estrella-immunopharma-inc-reports-material-event-63d41f7a04b3.html", "source_name": "Stock Titan", "published_at": "2026-06-30T21:10:00", "published_display": "30 Jun 2026 21:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Estrella Immunopharma, Inc. \u2013 BOATS:ESLAW", "summary": "This article provides financial information for Estrella Immunopharma, Inc. (ESLAW), specifically focusing on its enterprise value to EBITDA forward metric. The content indicates that the market is closed, with no trades observed, and presents this data as part of TradingView's f", "url": "https://www.tradingview.com/symbols/BOATS-ESLAW/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-30T20:10:00", "published_display": "30 Jun 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Estrella Immunopharma, Inc. Actuals & Estimates (NASDAQ:ESLA)", "summary": "This article provides an overview of Estrella Immunopharma, Inc. (ESLA) stock performance, including current trading price, historical highs and lows, and analyst forecasts. It details financial actuals and estimates for the company, covering income statements, balance sheets, an", "url": "https://www.tradingview.com/symbols/NASDAQ-ESLA/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-25T20:09:18", "published_display": "25 Jun 2026 20:09", "sentiment": "negative", "sentiment_pct": 40, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Estrella Immunopharma Inc (ESLA) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for Estrella Immunopharma Inc (ESLA), detailing its previous and expected future EPS. While the company's financial health, valuation, price momentum, and institutional confidence usually involve comprehensive data, relevant information ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-esla/earnings", "source_name": "TradingKey", "published_at": "2026-06-21T19:42:17", "published_display": "21 Jun 2026 19:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Estrella Immunopharma Inc (ESLA) Risk Assessment: Volatility, Financial Risk & Investment Risk", "summary": "This article provides a risk assessment for Estrella Immunopharma Inc (ESLA), detailing various volatility and risk metrics. It includes data points such as Beta vs S&P 500 index, Maximum Drawdown, Realised Volatility, and Daily Upside/Downside Volatility over different periods. ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-esla/risk-assesment", "source_name": "TradingKey", "published_at": "2026-06-21T19:39:34", "published_display": "21 Jun 2026 19:39", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Estrella Immunopharma Inc (ESLA) Financial Health: Profitability & Balance Sheet Analysis", "summary": "This article provides a financial health analysis of Estrella Immunopharma Inc (ESLA) through the lens of TradingKey. It highlights that critical financial data necessary to assess profitability, balance sheet, operational efficiency, growth potential, and shareholder returns hav", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-esla/financial-health", "source_name": "TradingKey", "published_at": "2026-06-21T19:10:54", "published_display": "21 Jun 2026 19:10", "sentiment": "negative", "sentiment_pct": 28, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Estrella Immunopharma Inc (ESLA) Institutional Confidence", "summary": "This article from TradingKey provides an overview of Estrella Immunopharma Inc (ESLA)'s institutional confidence. It details the institutional shareholding and shareholder activity, listing major holders like Eureka Therapeutics Inc, Renaissance Technologies LLC, Geode Capital Ma", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-esla/sentiment", "source_name": "TradingKey", "published_at": "2026-06-21T18:10:54", "published_display": "21 Jun 2026 18:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Estrella Immunopharma Inc (ESLA) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of Estrella Immunopharma Inc (ESLA), detailing its support, resistance, indicators, and moving averages. According to the analysis, various technical indicators and moving averages suggest a \"Sell\" signal for the stock, with 0 buy signal", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-esla/technical", "source_name": "TradingKey", "published_at": "2026-06-21T17:10:54", "published_display": "21 Jun 2026 17:10", "sentiment": "negative", "sentiment_pct": 19, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Estrella Immunopharma Inc (ESLA) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis for Estrella Immunopharma Inc (ESLA), noting that key financial ratios such as P/E, P/B, P/S, and P/CF are not yet disclosed by the company. It displays the current stock price, market capitalization, and indicates that the data is delay", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-esla/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-21T17:09:40", "published_display": "21 Jun 2026 17:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Estrella Immunopharma Inc (ESLAW) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution \u2014 TradingKey", "summary": "This article provides an overview of Estrella Immunopharma Inc (ESLAW), focusing on its revenue breakdown and company profile. It notes that relevant data regarding business segments, regional revenue, and profit contribution have not been disclosed by the company yet. The page a", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-eslaw/revenue", "source_name": "TradingKey", "published_at": "2026-06-18T11:41:06", "published_display": "18 Jun 2026 11:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Estrella Immunopharma Inc (ESLAW) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "This article details the shareholder structure of Estrella Immunopharma Inc (ESLAW), focusing on institutional holdings and major shareholders. It provides a quarterly breakdown of institutional share ownership and lists active institutional investors with their respective shares", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-eslaw/ownership", "source_name": "TradingKey", "published_at": "2026-06-18T11:41:06", "published_display": "18 Jun 2026 11:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Estrella Immunopharma Inc (ESLAW) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of Estrella Immunopharma Inc (ESLAW) focusing on its dividend and stock split history. It notes that the company has distributed $0.00 USD in dividends over the past five years and shows no data for past stock splits. The piece is primarily a dat", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-eslaw/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-18T11:41:06", "published_display": "18 Jun 2026 11:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Estrella Immunopharma Inc (ESLA) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of Estrella Immunopharma Inc's (ESLA) dividend history and stock split information. It notes that the company has not distributed any dividends over the past five years and has no recorded stock split events. The page also displays current stock ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-esla/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-18T02:40:28", "published_display": "18 Jun 2026 02:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Estrella Immunopharma Inc (ESLAW) Institutional Confidence", "summary": "This article provides details on the institutional confidence score for Estrella Immunopharma Inc (ESLAW), along with its stock performance data. It lists several institutional shareholders and their shareholdings or changes in holdings, highlighting notable movements such as red", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-eslaw/sentiment", "source_name": "TradingKey", "published_at": "2026-06-18T02:40:28", "published_display": "18 Jun 2026 02:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Estrella Immunopharma Inc (ESLAW) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for Estrella Immunopharma Inc (ESLAW), stating that relevant data for EPS, Revenue, and Net Profit forecasts have not yet been disclosed by the company. It notes the stock's current trading price and highlights the absence of key financi", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-eslaw/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T02:40:28", "published_display": "18 Jun 2026 02:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Estrella Immunopharma Inc. (ESLA) Stock Price | Live Quotes & Charts | NASDAQ", "summary": "This page provides live quotes and charts for Estrella Immunopharma Inc. (ESLA) stock. As of the data provided, ESLA is trading at $1.06, down $0.02 (-1.85%). The article notes that there are no analyst ratings or earning information currently available for the company.", "url": "https://stockstotrade.com/quote/ESLA", "source_name": "StocksToTrade", "published_at": "2026-06-13T16:09:56", "published_display": "13 Jun 2026 16:09", "sentiment": "negative", "sentiment_pct": 39, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Estrella Immunopharma (ESLA) sets virtual 2026 meeting to ratify auditor", "summary": "Estrella Immunopharma, Inc. (ESLA) will hold a virtual Combined 2025/2026 Annual Meeting of Stockholders on June 29, 2026, to ratify the appointment of Macias Gini & O\u2019Connell LLP as their independent registered public accounting firm for the fiscal year ending December 31, 2026.", "url": "https://www.stocktitan.net/sec-filings/ESLA/def-14a-estrella-immunopharma-inc-definitive-proxy-statement-11ec4954b9fb.html", "source_name": "Stock Titan", "published_at": "2026-05-27T21:39:37", "published_display": "27 May 2026 21:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Estrella CEO and CFO head to Plaza Hotel for investor meetings", "summary": "Estrella Immunopharma, a clinical-stage biopharmaceutical company, announced that its CEO and CFO will attend the D. Boral Capital 2026 Global Conference at The Plaza Hotel. They will be participating in one-on-one investor meetings to discuss the company's CD19 and CD22-targeted", "url": "https://www.stocktitan.net/news/ESLA/estrella-immunopharma-to-participate-in-the-d-boral-capital-global-19ufojqfo00a.html", "source_name": "Stock Titan", "published_at": "2026-05-24T08:10:17", "published_display": "24 May 2026 08:10", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Estrella Immunopharma, Inc. 1Q 2026: Net income $(2.29M), EPS $(0.05) \u2014 10-Q Summary", "summary": "Estrella Immunopharma, Inc. (ESLA) reported a net loss of $(2.29M) and a diluted loss per share of $(0.05) for the first quarter of 2026. This compares to a net loss of $(2.10M) and a diluted loss per share of $(0.06) in the same quarter last year. Key business highlights include", "url": "https://www.tradingview.com/news/tradingview:88655df7313e5:0-estrella-immunopharma-inc-1q-2026-net-income-2-29m-eps-0-05-10-q-summary/", "source_name": "TradingView", "published_at": "2026-05-18T10:39:18", "published_display": "18 May 2026 10:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[NT 10-Q] Estrella Immunopharma, Inc. SEC Filing", "summary": "Estrella Immunopharma, Inc. (ESLA) has filed a Form NT 10-Q, notifying the SEC of a late filing for its Quarterly Report on Form 10-Q for the period ended March 31, 2026. The company attributes the delay to administrative issues and expects to file the report within five calendar", "url": "https://www.stocktitan.net/sec-filings/ESLA/nt-10-q-estrella-immunopharma-inc-sec-filing-c5e46cfd1485.html", "source_name": "Stock Titan", "published_at": "2026-05-16T04:39:57", "published_display": "16 May 2026 04:39", "sentiment": "negative", "sentiment_pct": 39, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Estrella Immunopharma CFO Xu Jiandong buys $2,594 in stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxNanpmcXJ2dkx5SUxBcFN3bDVRUWtrVEZ5U3gyczJIM0MxblhPYzRzMnk4WFBSOFdqU2I2WHQ1OGVNVm83dkItVkU3d1kyTXI0R21zV2htXzZSeTdwbVE2RXNLTWlzcF9rVTFZM25ZWUM5NnV1LXpEUTJxelNwQ2dpS3F1VktOb1hlUVRteE4xdnlSaldNUUprdTdwRm1IZVp6RkxJY0VOLTFqQXNqWnMwWGRheUtCejZjREgyczRn?oc=5", "source_name": "Investing.com", "published_at": "2026-04-29T07:00:00+00:00", "published_display": "29 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Estrella Immunopharma, Inc. (NASDAQ: ESLA) Receives Initiating Coverage with a Valuation of $12.00/Share from Zacks Small-Cap Research", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwJBVV95cUxOb3ZQeUc1b2NtaWhWZGJ5WnNqSmJpVXh5TUZJZkhxMTBYcTZtMktwd1AtbXNEcnd1Yi1rM2ZsNldEekZ1MWoxcXNRYUtxbU1Ld0tzeWJ2OUdYdkVnUTdrZURrS2pUNy1PcGswbHlpVWUyNk1DZ08xVG5CSG9MNzlDa2lOVlMtRW54dnU4ZmVqMF9ZaDNQekJRRmVYQ28zU1hTaklOaUd1XzBxVjJpS1kyT18wMG93MmJUeG1JWEdacXUxRGV5cEdHWmJZeV9DYUp4a2RSaFRreGZBc0pJaW02eGZVMnlBTVh1WHVOdHNDeGdpd3laTGc5TWlOQ0psSlFvdWl3TkphVFBoSzR6ZkN0YzZTSlZrcGM?oc=5", "source_name": "Business Wire", "published_at": "2026-03-23T07:00:00+00:00", "published_display": "23 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Estrella Immunopharma Announces Closing of $8.0 Million Registered Direct Offering and Concurrent Private Placement", "summary": "", "url": "https://news.google.com/rss/articles/CBMi6gFBVV95cUxQeGR0d1d6MjdNT3FsZzFIQUZHSGNfLTAyN3BRUjNYbWNJYlhaenR5bS12ZmJhb2wtb3NQYlZBNk5fdERhbjhsSXRJTkpZZ0wtMDJ0a3lrY2JSbFhsUHBiLVhlb1ZuX0taaGs0cXFybE9uSmg3MGY1R1hKNlhJM3NmVmpLZFFka3dnWDRCVTI0NTBXZTA5a1JzdjhmZXRCTHdhRndobE82U3hfMEhPWTlXSDlBLTZCQ0M4WW1mVThCY01RRnRIWHJJU2lGUlAtUnhPcDBhOGh4RkNham1pTjYyVjZWUHJrTl81NkE?oc=5", "source_name": "BioSpace", "published_at": "2026-01-07T08:00:00+00:00", "published_display": "07 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Estrella Immunopharma (ESLA) FDA Approvals, PDUFA Dates & Drug Alerts 2026", "summary": "", "url": "https://news.google.com/rss/articles/CBMiaEFVX3lxTE1GOEY4RHRWWHBVLVZaWVg2NVlwS1JURllKRlBSQXNDNWFhdy1MeWFnM25XZmxIYk1MMHd1ZnNVeFM5RE1OV2JYeEllMnkwcFJpZ3phWHEwclhuTW83Uk8yRHhzb1FicXBL?oc=5", "source_name": "MarketBeat", "published_at": "2025-07-10T03:16:04+00:00", "published_display": "10 Jul 2025 03:16", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Estrella Immunopharma (ESLA) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiU0FVX3lxTE9tUFdKM2E1S01qeDVIN0w3S19TMEhmaXdlZUZuTTVTLU1iRkJvdk0ya3Q2VDBFZzRxY0gxT21zY3llckVHMFp3Y0tfZzJ1MWdDYXJF?oc=5", "source_name": "Stock Titan", "published_at": "2025-05-01T18:06:39+00:00", "published_display": "01 May 2025 18:06", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T07:00:00+00:00", "published_display": "13 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 97, "total_relevant": 43, "sentiment_summary": {"positive": 2, "negative": 9, "neutral": 32, "score": 46, "total": 43, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 75, "events": [{"event": "general", "label": "Market update", "weight": 9.9, "count": 18}, {"event": "earnings", "label": "Earnings", "weight": 8.66, "count": 18}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 1.1, "count": 2}, {"event": "analyst", "label": "Analyst action", "weight": 1.1, "count": 2}, {"event": "capital_return", "label": "Capital return", "weight": 1.1, "count": 2}, {"event": "guidance", "label": "Guidance", "weight": 0.55, "count": 1}], "positive_events": 2, "negative_events": 9}, "market_context": {"has_market_context": true, "latest_close": 0.84, "latest_week": "2026-07-17", "one_week_move": -9.4, "four_week_move": -11.6, "twelve_week_move": -46.8, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": -0.717781, "market_dynamics_buy_signal": false, "relative_strength": -43.818524, "fair_value_gap": -53.3, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "negative", "expectation_probability": 42.6404, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-9.4% over one week, -11.6% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "negative", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 61, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "TradingKey", "count": 12}, {"label": "TradingView", "count": 10}, {"label": "Market source", "count": 6}, {"label": "Stock Titan", "count": 5}, {"label": "simplywall.st", "count": 2}, {"label": "GlobeNewswire", "count": 1}, {"label": "Pluang", "count": 1}, {"label": "Minichart", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 34}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 18}, {"label": "Earnings", "count": 18}, {"label": "Regulatory and legal", "count": 2}, {"label": "Analyst action", "count": 2}, {"label": "Capital return", "count": 2}, {"label": "Guidance", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "46/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "negative", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "75/100 classification confidence."}, {"label": "Company focus", "value": "34", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "0", "tone": "neutral", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-9.4% over one week, -11.6% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Enterprise value to EBIT forward of Estrella Immunopharma, Inc. \u2013 NASDAQ:ESLAW"}], "updated_at": "2026-07-23T03:38:48.061262+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}